Background: Since the beginning of the SARS-CoV 2 pandemic, there have been many reports of increased incidence of VTE (venous thromboembolism) and arterial events as a complication, which were the basis for the hypothesis that patients should receive higher doses of thromboprophylaxis (TP) or full anticoagulation.

Aims: To determine the incidence of thrombotic events (TE) in patients hospitalized for moderate or severe SARS-CoV2 disease (Covid-19).

Methods: Retrospective single center cohort study with adult patients with a positive rt-PCR for SARS-CoV2 , included as from the date of hospital admission due to Covid-19 and followed for 90 days or until death.

Results: A total of 1621 patients were included. The mean age was 68.7 years (SD 21.1) and 57% (913) were female, of which 6.5% (59) were pregnant. Overall mortality was 21.6% (348). The overall incidence of symptomatic thrombotics events within 90 days was 1.72% (28/1621, 95%CI 1.19-2.49%), whereas the incidence of pulmonary embolism (PE) was 0.98% (15, 95%CI 0.60-0.16%), deep venous thrombosis (DVT) 0.74% (11, 95%CI 0.42-0.12%), ischemic stroke 0.24% (4, 95%CI 0.09-0.65%) and ischemic arterial events 0.06% (1, 95%CI 0.008-0.43%). No acute coronary syndrome events were recorded. Median hospital stay length percentage under adequate TP was 78%.
The median time since positive rt-PCR for the thrombotic event to develop was 22 days (IQR 25th-75th 19-43 days).
Median hospital stay length percentage under adequate thromboprophylaxis was 78% (IQR 25th-75th 50-89%).

Conclusions: Unlike previous reports, the incidence of thrombotic events was low among our patients with moderate or severe Covid-19.

« Back to ISTH 2021 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/low-incidence-of-thrombotic-events-in-patients-with-covid19-a-cohort-study/